PMID: 375343Apr 23, 1979Paper

The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: dose-time-response relationships in man

Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie
I HillebrandP Berchtold

Abstract

In a double-blind quadruple cross-over study the effect of a new alpha-glucosidase inhibitor (BAY g 5421) on postprandial blood glucose, serum insulin, and serum triglyceride increases was tested in 24 male healthy volunteers. They received before a standardized breakfast 50, 100, or 200 mg of BAY g 5421 or a placebo per os. The dose-time-response relationships were calculated and the drug tolerance was assessed. There was a statistically significant inhibition of the postprandial increases of the blood glucose, serum insulin, and triglyceride values. Further analysis showed no dose-dependent effect of the drug on the blood glucose values, whereas the serum insulin and triglyceride values were affected in a dose-dependent fashion. The maximal inhibitory effect on the serum insulin levels occurred 69 min after breakfast and on the serum triglyceride levels 104 min after breakfast. One hundred and 200 mg of BAY g 5421 were equally inhibitory-effective on the serum insulin levels, whereas the highest dose used was markedly more effective on serum triglyceride values than lower doses. Based on these results, a dosage of 100--200 mg of BAY g 5421/meal is recommended for clinical trials in metabolic diseases.

References

Oct 1, 1977·Die Naturwissenschaften·D D SchmidtD Schäfer
Apr 23, 1979·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·I HillebrandP Berchtold
Jun 1, 1978·Computer Programs in Biomedicine·D W HosmerS Lemeshow
Sep 15, 1965·Klinische Wochenschrift·F MelaniE F Pfeiffer

❮ Previous
Next ❯

Citations

Jan 1, 1986·European Journal of Clinical Pharmacology·I E Walter-SackN Zoellner
Dec 9, 1981·Clinica Chimica Acta; International Journal of Clinical Chemistry·I SuehiroS Baba
Jul 1, 1983·Pharmacology, Biochemistry, and Behavior·Z Glick, G A Bray
Aug 1, 1986·Pharmacology, Biochemistry, and Behavior·Z GlickU Sod-Moriah
Feb 11, 2005·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Sandro GentileRoberto Torella
Aug 1, 1987·Clinical and Experimental Pharmacology & Physiology·F P KennedyJ E Gerich
Mar 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·N HottaN Sakamoto
May 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·N HottaN Sakamoto
Apr 18, 2000·Journal of the American Veterinary Medical Association·R W NelsonC Briggs
Jul 1, 1997·Clinical Therapeutics·S KageyamaS Nakano
Oct 26, 2014·Journal of Feline Medicine and Surgery·Ranee SinghJohn M Morton
Feb 28, 2001·Diabetes, Obesity & Metabolism·M MalaguarneraG Pistone
Mar 1, 1987·Diabetic Medicine : a Journal of the British Diabetic Association·I Hillebrand
Dec 22, 1999·Endocrine Reviews·G A Bray, F L Greenway
Mar 12, 2016·Experimental & Molecular Medicine·Pia V RöderWeiping Han
Feb 6, 2008·Expert Review of Cardiovascular Therapy·Markolf Hanefeld, Frank Schaper
Jan 1, 1979·Bulletin of Environmental Contamination and Toxicology·M T FinleyR E Christensen
Dec 3, 1999·British Journal of Clinical Pharmacology·M MalaguarneraG Mazzoleni
Aug 1, 1994·European Journal of Clinical Investigation·W LeonhardtJ Schulze
Jan 1, 1985·Acta Medica Scandinavica. Supplementum·T William-Olsson
May 1, 1984·Biochemical Pharmacology·N HaugaardG Wildey
May 1, 1990·Diabetes Research and Clinical Practice·Y OkabayashiM Otsuki
Dec 1, 1988·Metabolism: Clinical and Experimental·P R HoltD P Kotler
Nov 25, 2004·Best Practice & Research. Clinical Gastroenterology·L Van GaalH J Verkade
Nov 27, 1981·Science·A L Demain

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.